Avalanche Biotechnologies (AAVL) Misses Q1 EPS by 18c

Avalanche Biotechnologies (NASDAQ: AAVL) reported Q1 EPS of ($0.57), $0.18 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $265 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Avalanche Biotechnologies (AAVL) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• JetBlue Airways (JBLU) stock dips as revenue declines
• Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates